Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.
Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback